Key information

🔎 Fund Overview

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The Company’s pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, EOS-448, also known as GSK4428859A, is an antagonist of T-cell immunoreceptor with lg and ITIM domains, an immune checkpoint with multiple mechanisms of action. The Company is also advancing inupadenant, a next generation adenosine A2A receptor antagonist tailored to overcome the specific adenosine-mediated immunosuppression. It is investigating inupadenant in an open-label multi-arm Phase I/IIa clinical trial in adult cancer patients with advanced solid tumors.